TENAYA THERAPEUTICS INC

CEO Ali Faraz’s zero‑price buy of 122k Tenaya shares signals insider confidence amid a 46% YTD decline—investors should watch upcoming clinical milestones for a potential turnaround.

CEO Ali Faraz’s May 18 insider sell at Tenaya Therapeutics is a routine tax‑cover move, not a red flag—investors should focus on clinical milestones and market volatility.

Column Group III GP trims Tenaya holdings amid quiet price swings—discover how strategic rebalancing may impact investor confidence and future prospects.

Column Group III GP, LP’s insider sales of Tenaya shares signal strategic divestment amid a price dip—an insider move that could impact short‑term volatility.

Insider sales at Tenaya Therapeutics reveal a structured divestment, but the large remaining stake keeps the biotech poised for future funding and partnership moves.

Tenaya Therapeutics insider buying: SVP Higa’s 2026 vesting & option grant shows long‑term confidence amid market dips, hinting at future upside.